234 related articles for article (PubMed ID: 1375134)
1. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Eliopoulos N; Cournoyer D; Momparler RL
Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Chabot GG; Bouchard J; Momparler RL
Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
[No Abstract] [Full Text] [Related]
6. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
7. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
8. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Momparler RL; Laliberté J
Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
10. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Momparler RL; Onetto-Pothier N; Momparler LF
Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231
[TBL] [Abstract][Full Text] [Related]
13. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D; Carpi FM; Pucciarelli S; Polzonetti V; Polidori P; Vilar S; Williams B; Costanzi S; Vincenzetti S
Int J Biol Macromol; 2014 Feb; 63():64-74. PubMed ID: 24183806
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds.
McCormack JJ; Marquez VE; Liu PS; Vistica DT; Driscoll JS
Biochem Pharmacol; 1980 Mar; 29(5):830-2. PubMed ID: 20227965
[No Abstract] [Full Text] [Related]
15. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Momparler RL; Momparler LF; Samson J
Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
[TBL] [Abstract][Full Text] [Related]
17. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1994 Apr; 5(2):223-8. PubMed ID: 7519483
[TBL] [Abstract][Full Text] [Related]
19. Ara-C metabolism: implications for drug resistance and drug interactions.
Chabner BA; Hande KR; Drake JC
Bull Cancer; 1979; 66(1):89-92. PubMed ID: 420952
[TBL] [Abstract][Full Text] [Related]
20. Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination.
Krajewska E; Shugar D
Acta Biochim Pol; 1975; 22(2):185-94. PubMed ID: 1098340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
